Ethchlorvynol

Jump to navigation Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
Ethchlorvynol
Clinical data
Routes of
administration
Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding35-50%
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC7H9ClO
Molar mass144.598 g/mol

WikiDoc Resources for Ethchlorvynol

Articles

Most recent articles on Ethchlorvynol

Most cited articles on Ethchlorvynol

Review articles on Ethchlorvynol

Articles on Ethchlorvynol in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Ethchlorvynol

Images of Ethchlorvynol

Photos of Ethchlorvynol

Podcasts & MP3s on Ethchlorvynol

Videos on Ethchlorvynol

Evidence Based Medicine

Cochrane Collaboration on Ethchlorvynol

Bandolier on Ethchlorvynol

TRIP on Ethchlorvynol

Clinical Trials

Ongoing Trials on Ethchlorvynol at Clinical Trials.gov

Trial results on Ethchlorvynol

Clinical Trials on Ethchlorvynol at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Ethchlorvynol

NICE Guidance on Ethchlorvynol

NHS PRODIGY Guidance

FDA on Ethchlorvynol

CDC on Ethchlorvynol

Books

Books on Ethchlorvynol

News

Ethchlorvynol in the news

Be alerted to news on Ethchlorvynol

News trends on Ethchlorvynol

Commentary

Blogs on Ethchlorvynol

Definitions

Definitions of Ethchlorvynol

Patient Resources / Community

Patient resources on Ethchlorvynol

Discussion groups on Ethchlorvynol

Patient Handouts on Ethchlorvynol

Directions to Hospitals Treating Ethchlorvynol

Risk calculators and risk factors for Ethchlorvynol

Healthcare Provider Resources

Symptoms of Ethchlorvynol

Causes & Risk Factors for Ethchlorvynol

Diagnostic studies for Ethchlorvynol

Treatment of Ethchlorvynol

Continuing Medical Education (CME)

CME Programs on Ethchlorvynol

International

Ethchlorvynol en Espanol

Ethchlorvynol en Francais

Business

Ethchlorvynol in the Marketplace

Patents on Ethchlorvynol

Experimental / Informatics

List of terms related to Ethchlorvynol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Ethchlorvynol is a sedative and hypnotic drug. It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists.

Along with expected sedative effects of relaxation and drowsiness ethchlorvynol can cause skin rashes, faintness, restlessness and euphoria. Early adjustment side effects can include nausea and vomiting, numbness, blurred vision, stomach pains and temporary dizziness. An overdose is marked by confusion, fever, peripheral numbness and weakness, reduced coordination and muscle control, slurred speech, reduced heartbeat.

It is addictive and after prolonged use can cause withdrawal symptoms including convulsions, hallucinations, and memory loss. Due to these problems, it is unusual for ethchlorvynol to be prescribed for periods exceeding seven days.

Ethchlorvynol is a member of the class of sedative-hypnotic tertiary carbinols, which inludes methylparafynol. It is not a barbituric acid derivative. The systematic name of ethchlorvynol is usually given as ethyl 2-chlorovinyl ethynyl carbinol or 1-chloro-3-ethyl-1-penten-4-yl-3-ol. Its empirical formula is C7H9ClO. In the United States Abbott Laboratories used to sell it under the tradename Placidyl. During their heyday, they were known on the street as "jelly-bellies". Since Abbott and Banner Pharmacaps, which manufactured the generic version, discontinued production in 1999, ethchlorvynol is no longer available in the United States.

Ethchlorvynol as it relates to William Rehnquist

Placidyl is the drug prescribed for William Rehnquist as treatment of insomnia after back surgery in 1971, according to FBI files obtained after Rehnquist's death. Before he was hospitalized in 1981, court employees noticed that Rehnquist's speech was slurred and that he seemed to be having mental lapses. The hospital doctors took him off the medication, causing withdrawal symptoms, which included hallucinations.[2]

One of the physicians who treated Rehnquist for Placidyl withdrawal, according to the FBI files, described auditory hallucinations in the form of voices discussing him outside his hospital room. At one point the Justice tried to flee the hospital in his pajamas, specifically because of the mistaken belief that the CIA was plotting against him.[3]

Notes

  1. Green List: Annex to the annual statistical report on psychotropic substances (form P) 23rd edition. August 2003. International Narcotics Board, Vienna International Centre. Accessed 1 September 2005 (UTC)
  2. Legal Times. Accessed 4 January 2007 (UTC)
  3. Sherman, Mark (Jan 04 2007). "FBI Files: Rehnquist Had Hallucinations". Breitbart.com. Retrieved 2007-01-05. Unknown parameter |coauthors= ignored (help); Check date values in: |date= (help)

References


Template:Sedative